Blood Journal

Overview

publication venue for

• An intrasinusoidal extracavitary variant of primary effusion lymphoma. 2017
• Placental/umbilical cord blood for unrelated-donor bone marrow reconstitution: relevance of nucleated red blood cells. 2002
• Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes. 1994
• How I use Maintenance Therapy in Acute Myeloid Leukemia. 2024
• Disruption of cotranscriptional splicing suggests that RBM39 is a therapeutic target in acute lymphoblastic leukemia. 2024
• Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO Cohort Study analysis. 2024
• Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. 2024
• Risk Prediction for Clonal Cytopenia: Multicenter Real-World Evidence. 2024
• GM-CSF receptor expression determines opposing innate memory phenotypes at different stages of myelopoiesis..  143. 2024
• Randomized Bendamustine-Rituximab(R) + Bortezomib Induction and R + Lenalidomide Maintenance for Mantle Cell Lymphoma. 2024
• Motive and Opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements-an LLMPP study. 2024
• T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia. 2024
• Circulating Hematopoietic Stem/Progenitor Cells subsets contribute to human hematopoietic homeostasis. 2024
• Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study..  142. 2023
• The hepatokine FGL1 regulates hepcidin and iron metabolism during anemia in mice by antagonizing BMP signaling. 2023
• Dual-receptor T cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML. 2023
• Spatial Mapping of Human Hematopoiesis at Single Cell Resolution Reveals Aging-Associated Topographic Remodeling. 2023
• Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia..  142. 2023
• Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in ELEVATE-RR. 2023
• PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma. 2023
• Novel extragenic genomic safe harbors for precise therapeutic T-cell engineering..  141. 2023
• CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis..  141. 2023
• DNA polymerase θ protects leukemia cells from metabolically induced DNA damage..  141. 2023
• Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures..  141. 2023
• Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL..  141. 2023
• Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRPα checkpoint blocker..  141. 2023
• A phase 2 study of interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract..  141. 2023
• Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the Acute Myeloid Leukemia burden. 2023
• Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma. 2023
• Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy..  140. 2022
• Venetoclax and idasanutlin in relapsed/refractory AML: a non-randomized, open-label phase 1b trial. 2022
• GENETIC SUBGROUPS INFORM ON PATHOBIOLOGY IN ADULT AND PEDIATRIC BURKITT LYMPHOMA. 2022
• A MIR17HG-derived Long Noncoding RNA Provides an Essential Chromatin Scaffold for Protein Interaction and Myeloma Growth. 2022
• The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee..  140. 2022
• A TCR mimic CAR T cell specific for NDC80 is broadly reactive with solid tumors and hematologic malignancies..  140. 2022
• Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia..  140. 2022
• Endothelial-leukemia interactions remodel drug responses uncovering T-ALL vulnerabilities. 2022
• Outcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC..  140. 2022
• Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine. 2022
• CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR..  140. 2022
• The ERK2-DBP domain opposes pathogenesis of a mouse JAK2V617F-driven myeloproliferative neoplasm..  140. 2022
• Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel. 2022
• BMP2/SMAD pathway activation in JAK2/p53-mutant megakaryocyte/erythroid progenitors promotes leukemic transformation..  139. 2022
• Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort..  139. 2022
• Early intestinal microbial features are associated with CD4 T-cell recovery after allogeneic hematopoietic transplant..  139. 2022
• Alloreactive T cells deficient of the short-chain fatty acid receptor GPR109A induce less graft-versus-host disease..  139. 2022
• Coordinated missplicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome..  139. 2022
• Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL..  139. 2022
• Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation..  139. 2022
• ORP4L is a prerequisite for the induction of T-cell leukemogenesis associated with human T-cell leukemia virus 1..  139. 2022
• Guiding the Global Evolution of Cytogenetic Testing for Hematologic Malignancies. 2022
• Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma..  139. 2022
• Oral azacitidine prolongs survival of patients with AML in remission independent of measurable residual disease status. 2022
• RARγ activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway..  139. 2022
• 2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document. 2021
• Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma. 2021
• Phase II biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. 2021
• Oncogenic role of SOX9-DHCR24-cholesterol biosynthesis axis in IGH-BCL2 positive diffuse large B-cell lymphomas. 2021
• The Menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML. 2021
• B-cell receptor signaling and genetic lesions in TP53 and CDKN2A/CDKN2B cooperate in Richter transformation..  138. 2021
• Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy..  138. 2021
• Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project..  138. 2021
• Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML..  138. 2021
• A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML..  137. 2021
• Acalabrutinib in treatment-naive chronic lymphocytic leukemia..  137. 2021
• ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models..  137. 2021
• Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models..  137. 2021
• Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL..  137. 2021
• Molecular Classification Improves Risk Assessment in Adult BCR-ABL1-negative B-ALL. 2021
• Reduced expression of annexin A2 is associated with impaired cell surface fibrinolysis and venous thromboembolism..  137. 2021
• Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors..  137. 2021
• KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas. 2021
• Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children's Oncology Group..  137. 2021
• Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia..  137. 2021
• BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells..  137. 2021
• CD4+ T-cell reconstitution predicts survival outcomes after acute graft-versus-host-disease: a dual-center validation..  137. 2021
• Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL..  137. 2021
• Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma..  137. 2021
• High frequency of clonal hematopoiesis in Erdheim-Chester disease..  137. 2021
• Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers..  137. 2021
• Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set..  136. 2020
• SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein..  136. 2020
• Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma..  136. 2020
• MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma..  136. 2020
• Yap1-Scribble polarization is required for hematopoietic stem cell division and fate..  136. 2020
• Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms..  136. 2020
• Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial)..  136. 2020
• Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome..  136. 2020
• Outcomes of COVID-19 in patients with CLL: a multicenter international experience..  136. 2020
• Megakaryocyte TGFβ1 partitions erythropoiesis into immature progenitor/stem cells and maturing precursors..  136. 2020
• Cereblon harnesses Myc-dependent bioenergetics and activity of CD8+ T lymphocytes..  136. 2020
• Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study..  136. 2020
• COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection..  136. 2020
• HLA-B leader and survivorship after HLA-mismatched unrelated donor transplantation..  136. 2020
• The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD..  136. 2020
• Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial..  135. 2020
• Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapy..  135. 2020
• Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results..  135. 2020
• Rare and private spliceosomal gene mutations drive partial, complete, and dual phenocopies of hotspot alterations..  135. 2020
• HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms..  135. 2020
• Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL..  134. 2019
• The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative..  134. 2019
• Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma..  134. 2019
• Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL..  134. 2019
• CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma..  134. 2019
• Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark..  134. 2019
• Identification and transcriptome analysis of erythroblastic island macrophages..  134. 2019
• PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas..  133. 2019
• PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype..  133. 2019
• Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia..  133. 2019
• Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab..  133. 2019
• Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma..  133. 2019
• Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma..  133. 2019
• Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma..  133. 2019
• Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study..  133. 2019
• A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma..  133. 2019
• Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma..  133. 2019
• Arterial thromboembolic events preceding the diagnosis of cancer in older persons..  133. 2018
• Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma..  133. 2018
• Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib..  133. 2018
• Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR..  133. 2018
• Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016..  133. 2018
• Nrf2 regulates CD4⁺ T cell-induced acute graft-versus-host disease in mice..  132. 2018
• Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy..  133. 2018
• Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease..  133. 2018
• Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma..  132. 2018
• Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma..  132. 2018
• International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease..  132. 2018
• SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery..  132. 2018
• PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival..  132. 2018
• Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis..  132. 2018
• CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET..  132. 2018
• Extracellular vesicles in DLBCL provide abundant clues to aberrant transcriptional programming and genomic alterations..  132. 2018
• Blood-induced bone loss in murine hemophilic arthropathy is prevented by blocking the iRhom2/ADAM17/TNF-α pathway..  132. 2018
• B-cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation..  131. 2018
• High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML..  131. 2018
• Impact of gut colonization with butyrate-producing microbiota on respiratory viral infection following allo-HCT..  131. 2018
• NADPH oxidase activation regulates apoptotic neutrophil clearance by murine macrophages..  131. 2018
• Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study..  131. 2018
• Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas..  131. 2018
• Antiphospholipid antibodies induce thrombosis by PP2A activation via apoER2-Dab2-SHC1 complex formation in endothelium..  131. 2018
• LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML..  131. 2018
• Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience..  131. 2018
• A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL..  131. 2018
• Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma..  131. 2017
• Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma..  131. 2017
• Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies..  131. 2017
• A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia..  130. 2017
• Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study..  130. 2017
• Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: a PIDTC natural history study..  130. 2017
• Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma..  130. 2017
• Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations..  130. 2017
• Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN..  130. 2017
• High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis..  130. 2017
• Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States..  130. 2017
• Loss of thymic innate lymphoid cells leads to impaired thymopoiesis in experimental graft-versus-host disease..  130. 2017
• Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia..  130. 2017
• Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response..  130. 2017
• Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML..  130. 2017
• Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells..  130. 2017
• Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults..  130. 2017
• GLI3 repressor determines Hedgehog pathway activation and is required for response to SMO antagonist glasdegib in AML..  129. 2017
• A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma..  129. 2017
• Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease..  129. 2017
• Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma..  129. 2017
• Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL..  129. 2017
• Validation of single nucleotide polymorphisms in invasive aspergillosis following hematopoietic cell transplantation..  129. 2017
• Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia..  129. 2017
• Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study..  129. 2017
• Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma..  129. 2017
• BCAP inhibits proliferation and differentiation of myeloid progenitors in the steady state and during demand situations..  129. 2017
• International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease..  129. 2017
• Aid is a key regulator of myeloid/erythroid differentiation and DNA methylation in hematopoietic stem/progenitor cells..  129. 2017
• Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma..  129. 2017
• Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma..  128. 2016
• Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103..  128. 2016
• Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma..  128. 2016
• Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors..  128. 2016
• Hyperfibrinolysis increases blood-brain barrier permeability by a plasmin- and bradykinin-dependent mechanism..  128. 2016
• Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma..  128. 2016
• Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma..  128. 2016
• Evolution of acute myelogenous leukemia stem cell properties after treatment and progression..  128. 2016
• Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy..  128. 2016
• The genetics of nodal marginal zone lymphoma..  128. 2016
• Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations..  128. 2016
• Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial..  128. 2016
• Immunoregulatory roles of versican proteolysis in the myeloma microenvironment..  128. 2016
• CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma..  127. 2016
• Patterns of expression of factor VIII and von Willebrand factor by endothelial cell subsets in vivo..  128. 2016
• Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma..  128. 2016
• IL-4 enhances expression and function of surface IgM in CLL cells..  127. 2016
• Comprehensive mutational profiling of core binding factor acute myeloid leukemia..  127. 2016
• Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting..  127. 2016
• miR-181a negatively regulates NF-κB signaling and affects activated B-cell-like diffuse large B-cell lymphoma pathogenesis..  127. 2016
• HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment..  127. 2016
• Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis..  127. 2016
• Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure..  127. 2016
• Strategies that delay or prevent the timely availability of affordable generic drugs in the United States..  127. 2016
• Postibrutinib outcomes in patients with mantle cell lymphoma..  127. 2016
• Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups..  127. 2016
• Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma..  127. 2016
• Increased DNA methylation of Dnmt3b targets impairs leukemogenesis..  127. 2016
• Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors..  127. 2015
• Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas..  127. 2015
• The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy..  127. 2015
• A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia..  126. 2015
• Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts..  127. 2015
• NADPH oxidase controls neutrophilic response to sterile inflammation in mice by regulating the IL-1α/G-CSF axis..  126. 2015
• Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias..  126. 2015
• Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infection..  126. 2015
• Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia..  126. 2015
• Autophagy is induced upon platelet activation and is essential for hemostasis and thrombosis..  126. 2015
• Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia..  126. 2015
• Plerixafor+G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy..  126. 2015
• Recurrent CDKN1B (p27) mutations in hairy cell leukemia..  126. 2015
• Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results..  126. 2015
• AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma..  126. 2015
• The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model..  125. 2015
• The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphoma..  125. 2015
• The tumor virus landscape of AIDS-related lymphomas..  125. 2015
• Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma..  125. 2015
• Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation..  125. 2015
• Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib..  125. 2015
• Crucial role for the VWF A1 domain in binding to type IV collagen..  125. 2015
• miR-29a maintains mouse hematopoietic stem cell self-renewal by regulating Dnmt3a..  125. 2015
• HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma..  125. 2015
• R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma..  125. 2015
• Acute myeloid leukemia ontogeny is defined by distinct somatic mutations..  125. 2014
• Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells..  125. 2014
• Integrin αvβ3 acting as membrane receptor for thyroid hormones mediates angiogenesis in malignant T cells..  125. 2014
• BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma..  125. 2014
• High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation..  125. 2014
• Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia..  125. 2014
• A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders..  124. 2014
• Isolation and transcriptome analyses of human erythroid progenitors: BFU-E and CFU-E..  124. 2014
• HLA-C expression levels define permissible mismatches in hematopoietic cell transplantation..  124. 2014
• IRAK-4 and MyD88 deficiencies impair IgM responses against T-independent bacterial antigens..  124. 2014
• The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia..  125. 2014
• Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms..  125. 2014
• A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients..  124. 2014
• FOXO1 repression contributes to block of plasma cell differentiation in classical Hodgkin lymphoma..  124. 2014
• Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis..  124. 2014
• JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis..  124. 2014
• Mutations in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD)..  124. 2014
• Dominant unit CD34+ cell dose predicts engraftment after double-unit cord blood transplantation and is influenced by bank practice..  124. 2014
• Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis..  124. 2014
• Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease..  124. 2014
• Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts..  124. 2014
• Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis..  124. 2014
• A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistance..  124. 2014
• Genetic alterations of the cohesin complex genes in myeloid malignancies..  124. 2014
• Platelet diameters in inherited thrombocytopenias: analysis of 376 patients with all known disorders..  124. 2014
• High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis..  124. 2014
• Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations..  124. 2014
• A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma..  124. 2014
• MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis..  124. 2014
• The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation..  124. 2014
• Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma..  124. 2014
• ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes..  124. 2014
• BMP signaling balances murine myeloid potential through SMAD-independent p38MAPK and NOTCH pathways..  124. 2014
• Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia..  124. 2014
• A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia..  123. 2014
• Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis..  123. 2014
• A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias..  123. 2014
• Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling..  123. 2014
• Image-guided intrathymic injection of multipotent stem cells supports lifelong T-cell immunity and facilitates targeted immunotherapy..  123. 2014
• Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin..  123. 2014
• Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms..  123. 2014
• A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)..  123. 2014
• Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma..  123. 2014
• Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia..  123. 2014
• Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice..  123. 2014
• Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms..  123. 2014
• Safe mobilization of CD34+ cells in adults with β-thalassemia and validation of effective globin gene transfer for clinical investigation..  123. 2014
• Elavl1a regulates zebrafish erythropoiesis via posttranscriptional control of gata1..  123. 2014
• Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors..  123. 2014
• Leukocyte cell-derived chemotaxin 2 (LECT2)-associated amyloidosis is a frequent cause of hepatic amyloidosis in the United States..  123. 2014
• Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy..  123. 2014
• Identification of a permissible HLA mismatch in hematopoietic stem cell transplantation..  123. 2014
• Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes..  123. 2014
• A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia..  123. 2013
• A targeted mutational landscape of angioimmunoblastic T-cell lymphoma..  123. 2013
• Exosomes from red blood cell units bind to monocytes and induce proinflammatory cytokines, boosting T-cell responses in vitro..  123. 2013
• Cooperative transcriptional repression by BCL6 and BACH2 in germinal center B-cell differentiation..  123. 2013
• An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era..  123. 2013
• Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy..  123. 2013
• Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI..  122. 2013
• EZH2 mutations are frequent and represent an early event in follicular lymphoma..  122. 2013
• BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders..  122. 2013
• Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma..  122. 2013
• PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma..  122. 2013
• Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome..  122. 2013
• Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality..  122. 2013
• MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program..  122. 2013
• Interleukin-7 is produced by afferent lymphatic vessels and supports lymphatic drainage..  122. 2013
• Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies..  122. 2013
• Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies..  122. 2013
• Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma..  122. 2013
• Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis..  122. 2013
• Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes..  122. 2013
• Integrated phosphoproteomic and metabolomic profiling reveals NPM-ALK-mediated phosphorylation of PKM2 and metabolic reprogramming in anaplastic large cell lymphoma..  122. 2013
• MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma..  122. 2013
• Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a..  122. 2013
• Pursuing the curative blueprint for early myeloma..  122. 2013
• Critical role of sphingosine-1-phosphate receptor 2 (S1PR2) in acute vascular inflammation..  122. 2013
• Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia..  121. 2013
• GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia..  121. 2013
• Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes..  121. 2013
• Downregulation of FOXP1 is required during germinal center B-cell function..  121. 2013
• A novel syndrome of congenital sideroblastic anemia, B-cell immunodeficiency, periodic fevers, and developmental delay (SIFD)..  122. 2013
• Improved ex vivo expansion of adult hematopoietic stem cells by overcoming CUL4-mediated degradation of HOXB4..  121. 2013
• Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program..  121. 2013
• BCL6 breaks occur at different AID sequence motifs in Ig-BCL6 and non-Ig-BCL6 rearrangements..  121. 2013
• IL-12 receptor β1 deficiency alters in vivo T follicular helper cell response in humans..  121. 2013
• Targeting B-cell anergy in chronic lymphocytic leukemia..  121. 2013
• MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program..  121. 2013
• An efferocytosis-induced, IL-4-dependent macrophage-iNKT cell circuit suppresses sterile inflammation and is defective in murine CGD..  121. 2013
• Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant..  121. 2013
• Isolation and functional characterization of human erythroblasts at distinct stages: implications for understanding of normal and disordered erythropoiesis in vivo..  121. 2013
• miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling..  121. 2013
• Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?.  121. 2013
• CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study..  121. 2013
• Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia..  121. 2013
• MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction..  121. 2013
• BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma..  121. 2013
• The central nervous system is a target of acute graft versus host disease in mice..  121. 2013
• High-dimensional immunomonitoring models of HIV-1-specific CD8 T-cell responses accurately identify subjects achieving spontaneous viral control..  121. 2012
• Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia..  121. 2012
• The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort..  121. 2012
• Human ESC-derived hemogenic endothelial cells undergo distinct waves of endothelial to hematopoietic transition..  121. 2012
• Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study..  121. 2012
• WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions..  121. 2012
• DNA methylation changes are a late event in acute promyelocytic leukemia and coincide with loss of transcription factor binding..  121. 2012
• SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia..  121. 2012
• Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes..  120. 2012
• Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP..  120. 2012
• Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone..  120. 2012
• Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation..  120. 2012
• Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells..  120. 2012
• t(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growth..  120. 2012
• Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study..  120. 2012
• CD16+ monocytes control T-cell subset development in immune thrombocytopenia..  120. 2012
• Defective regulatory B-cell compartment in patients with immune thrombocytopenia..  120. 2012
• CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900..  120. 2012
• Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas..  120. 2012
• Mechanisms of resistance to high and low linear energy transfer radiation in myeloid leukemia cells..  120. 2012
• Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations..  120. 2012
• Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma..  120. 2012
• Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4..  120. 2012
• Development of a vascular niche platform for expansion of repopulating human cord blood stem and progenitor cells..  120. 2012
• FGF-2 expands murine hematopoietic stem and progenitor cells via proliferation of stromal cells, c-Kit activation, and CXCL12 down-regulation..  120. 2012
• Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation..  120. 2012
• Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias..  120. 2012
• Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia..  119. 2012
• Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopenia..  120. 2012
• Identification of LMO2 transcriptome and interactome in diffuse large B-cell lymphoma..  119. 2012
• Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1..  119. 2012
• Abnormalities in IgA and IgM are associated with treatment-resistant ITP..  119. 2012
• Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia..  119. 2012
• Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome..  119. 2012
• Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era..  119. 2012
• Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma..  119. 2012
• Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma..  119. 2012
• Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy..  119. 2012
• Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning..  119. 2012
• Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes..  119. 2012
• Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation..  119. 2012
• In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation..  119. 2012
• Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort..  119. 2012
• Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas..  119. 2012
• Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database..  119. 2012
• Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma..  119. 2011
• Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation..  119. 2011
• Expansion of CD8+ T cells lacking Sema4D/CD100 during HIV-1 infection identifies a subset of T cells with decreased functional capacity..  119. 2011
• Phosphorylation of the myosin IIA tailpiece regulates single myosin IIA molecule association with lytic granules to promote NK-cell cytotoxicity..  118. 2011
• Plasmodium falciparum STEVOR proteins impact erythrocyte mechanical properties..  119. 2011
• The principal results of the International Immune Tolerance Study: a randomized dose comparison..  119. 2011
• Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma..  119. 2011
• Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation..  119. 2011
• SYK inhibition and response prediction in diffuse large B-cell lymphoma..  118. 2011
• Transfusion of human volunteers with older, stored red blood cells produces extravascular hemolysis and circulating non-transferrin-bound iron..  118. 2011
• Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia..  119. 2011
• CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death..  118. 2011
• Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia..  118. 2011
• Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions..  118. 2011
• Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia..  118. 2011
• Anti-IL6-receptor-alpha (tocilizumab) does not inhibit human monocyte-derived dendritic cell maturation or alloreactive T-cell responses..  118. 2011
• Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias..  118. 2011
• Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen..  118. 2011
• The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia..  118. 2011
• Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target..  118. 2011
• TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms..  118. 2011
• Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC..  118. 2011
• Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias..  118. 2011
• Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies..  118. 2011
• DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation..  118. 2011
• Notch1 controls macrophage recruitment and Notch signaling is activated at sites of endothelial cell anastomosis during retinal angiogenesis in mice..  118. 2011
• Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)..  118. 2011
• Hypoxia-inducible factor-1 drives annexin A2 system-mediated perivascular fibrin clearance in oxygen-induced retinopathy in mice..  118. 2011
• Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report..  118. 2011
• HLA mismatch direction in cord blood transplantation: impact on outcome and implications for cord blood unit selection..  118. 2011
• Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid..  118. 2011
• Hyperhomocysteinemia impairs endothelium-derived hyperpolarizing factor-mediated vasorelaxation in transgenic cystathionine beta synthase-deficient mice..  118. 2011
• Ddx18 is essential for cell-cycle progression in zebrafish hematopoietic cells and is mutated in human AML..  118. 2011
• Deletion of Adam10 in endothelial cells leads to defects in organ-specific vascular structures..  118. 2011
• Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS)..  118. 2011
• Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML..  118. 2011
• Abrogation of donor T-cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL..  118. 2011
• Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study..  118. 2011
• Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary report..  117. 2011
• The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRb-dependent tumor-suppressive pathway..  117. 2011
• Smad1 signaling restricts hematopoietic potential after promoting hemangioblast commitment..  117. 2011
• A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia..  118. 2011
• Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset..  117. 2011
• A20 (TNFAIP3) genetic alterations in EBV-associated AIDS-related lymphoma..  117. 2011
• Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia..  117. 2011
• Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET..  117. 2011
• Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor-, granulocyte-macrophage colony-stimulating factor-, and interleukin-3-expressing NOD-SCID IL2Rγ(null) humanized mice..  117. 2011
• The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma..  117. 2011
• Normal bone marrow signal-transduction profiles: a requisite for enhanced detection of signaling dysregulations in AML..  117. 2011
• Notch is oncogenic dominant in T-cell acute lymphoblastic leukemia..  117. 2011
• Immune reconstitution is preserved in hematopoietic stem cell transplantation coadministered with regulatory T cells for GVHD prevention..  117. 2010
• Endothelial reticulon-4B (Nogo-B) regulates ICAM-1-mediated leukocyte transmigration and acute inflammation..  117. 2010
• Neoangiogenesis contributes to the development of hemophilic synovitis..  117. 2010
• Noxa mediates p18INK4c cell-cycle control of homeostasis in B cells and plasma cell precursors..  117. 2010
• Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations..  117. 2010
• Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts..  117. 2010
• Lunatic Fringe prolongs Delta/Notch-induced self-renewal of committed αβ T-cell progenitors..  117. 2010
• Enhanced erythropoiesis in Hfe-KO mice indicates a role for Hfe in the modulation of erythroid iron homeostasis..  117. 2010
• Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing..  117. 2010
• Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells..  117. 2010
• Impaired angiogenesis and altered Notch signaling in mice overexpressing endothelial Egfl7..  116. 2010
• Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways..  116. 2010
• Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1..  117. 2010
• T-cell receptor signals direct the composition and function of the memory CD8+ T-cell pool..  116. 2010
• EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis..  116. 2010
• CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset..  116. 2010
• Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs..  116. 2010
• Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma..  116. 2010
• Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia..  116. 2010
• Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents..  116. 2010
• A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma..  116. 2010
• Severe pandemic H1N1 and seasonal influenza in children and young adults with sickle cell disease..  116. 2010
• Immune activation induces immortalization of HTLV-1 LTR-Tax transgenic CD4+ T cells..  116. 2010
• Low-dose radiation augments vasculogenesis signaling through HIF-1-dependent and -independent SDF-1 induction..  116. 2010
• DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma..  116. 2010
• An in vivo model of double-unit cord blood transplantation that correlates with clinical engraftment..  116. 2010
• Depletion of L3MBTL1 promotes the erythroid differentiation of human hematopoietic progenitor cells: possible role in 20q- polycythemia vera..  116. 2010
• Bone loss caused by iron overload in a murine model: importance of oxidative stress..  116. 2010
• HS1 has a central role in the trafficking and homing of leukemic B cells..  116. 2010
• Concurrent visualization of trafficking, expansion, and activation of T lymphocytes and T-cell precursors in vivo..  116. 2010
• Leukemia regression by vascular disruption and antiangiogenic therapy..  116. 2010
• The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores..  116. 2010
• Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia..  116. 2010
• Canonical BMP signaling is dispensable for hematopoietic stem cell function in both adult and fetal liver hematopoiesis, but essential to preserve colon architecture..  115. 2010
• Platelets regulate lymphatic vascular development through CLEC-2-SLP-76 signaling..  116. 2010
• AKT1 and AKT2 maintain hematopoietic stem cell function by regulating reactive oxygen species..  115. 2010
• TRAF6 inhibits Th17 differentiation and TGF-beta-mediated suppression of IL-2..  115. 2010
• Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells..  116. 2010
• The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms..  115. 2010
• Transfusion of red blood cells after prolonged storage produces harmful effects that are mediated by iron and inflammation..  115. 2010
• Complement receptor 2/CD21- human naive B cells contain mostly autoreactive unresponsive clones..  115. 2010
• Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting..  115. 2010
• IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice..  115. 2010
• Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs..  115. 2010
• Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis..  115. 2010
• The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma..  115. 2010
• Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation..  115. 2010
• Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways..  115. 2010
• Akt1 and Akt2 promote peripheral B-cell maturation and survival..  115. 2009
• Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies..  115. 2009
• Mislocalization of SLP-76 leads to aberrant inflammatory cytokine and autoantibody production..  115. 2009
• Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma..  115. 2009
• Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug..  115. 2009
• Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia..  115. 2009
• BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt..  114. 2009
• Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation..  114. 2009
• Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells..  114. 2009
• Functionally distinct subsets of human NK cells and monocyte/DC-like cells identified by coexpression of CD56, CD7, and CD4..  114. 2009
• Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens..  114. 2009
• Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study..  115. 2009
• Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases..  114. 2009
• Bone marrow stem and progenitor cell contribution to neovasculogenesis is dependent on model system with SDF-1 as a permissive trigger..  114. 2009
• Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis..  114. 2009
• Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units..  114. 2009
• Cytolytic T cells induce ceramide-rich platforms in target cell membranes to initiate graft-versus-host disease..  114. 2009
• Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease..  114. 2009
• Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma..  114. 2009
• MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation..  114. 2009
• Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo..  114. 2009
• Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib..  114. 2009
• Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodies..  114. 2009
• The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways..  114. 2009
• Exposure of human megakaryocytes to high shear rates accelerates platelet production..  114. 2009
• Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells..  114. 2009
• Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies..  114. 2009
• Noninvasive in vivo imaging of CD4 cells in simian-human immunodeficiency virus (SHIV)-infected nonhuman primates..  114. 2009
• Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity..  113. 2009
• Transcription factor Zfx controls BCR-induced proliferation and survival of B lymphocytes..  113. 2009
• The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL..  113. 2009
• Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease..  113. 2009
• Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project..  113. 2009
• Skewing of X-inactivation ratios in blood cells of aging women is confirmed by independent methodologies..  113. 2009
• Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors..  113. 2009
• Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation..  113. 2009
• Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features..  113. 2009
• Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma..  113. 2009
• The structure of the ankyrin-binding site of beta-spectrin reveals how tandem spectrin-repeats generate unique ligand-binding properties..  113. 2009
• Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide..  113. 2008
• Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk..  113. 2008
• High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients..  113. 2008
• A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response..  113. 2008
• Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses after murine allogeneic bone marrow transplantation..  113. 2008
• Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP..  113. 2008
• Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells..  113. 2008
• Gene expression profiling of pulmonary mucosa-associated lymphoid tissue lymphoma identifies new biologic insights with potential diagnostic and therapeutic applications..  113. 2008
• Solid cancers after allogeneic hematopoietic cell transplantation..  113. 2008
• A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo..  113. 2008
• The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL..  113. 2008
• STAT-3 and ERK 1/2 phosphorylation are critical for T-cell alloactivation and graft-versus-host disease..  112. 2008
• Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study..  113. 2008
• Thalidomide and rituximab in Waldenstrom macroglobulinemia..  112. 2008
• IL-4 protein expression and basal activation of Erk in vivo in follicular lymphoma..  112. 2008
• Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma..  112. 2008
• Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia..  112. 2008
• A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease..  112. 2008
• The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies..  112. 2008
• Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers..  112. 2008
• PILAR is a novel modulator of human T-cell expansion..  112. 2008
• In vitro and in vivo evidence for shear-induced activation of latent transforming growth factor-beta1..  112. 2008
• Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV..  112. 2008
• Reversible disruption of BCL6 repression complexes by CD40 signaling in normal and malignant B cells..  112. 2008
• Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia..  112. 2008
• Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura..  112. 2008
• Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab..  111. 2008
• Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission..  112. 2008
• Synergistic interactions between interferon-gamma and TRAIL modulate c-FLIP in endothelial cells, mediating their lineage-specific sensitivity to thrombotic thrombocytopenic purpura plasma-associated apoptosis..  112. 2008
• Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data..  111. 2008
• Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis..  111. 2008
• Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study..  111. 2008
• High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia..  111. 2008
• EBV LMP2A affects LMP1-mediated NF-kappaB signaling and survival of lymphoma cells by regulating TRAF2 expression..  111. 2008
• The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target..  111. 2008
• CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy..  111. 2008
• KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor..  111. 2008
• Organ-derived dendritic cells have differential effects on alloreactive T cells..  111. 2008
• A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies..  111. 2007
• CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib..  111. 2007
• Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group..  111. 2007
• Indirect involvement of allergen-captured mast cells in antigen presentation..  111. 2007
• The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death..  111. 2007
• The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition..  111. 2007
• BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma..  111. 2007
• Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia..  111. 2007
• Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment..  111. 2007
• Locus control region elements HS1 and HS4 enhance the therapeutic efficacy of globin gene transfer in beta-thalassemic mice..  110. 2007
• Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences..  110. 2007
• Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma..  110. 2007
• An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells..  110. 2007
• Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8)..  110. 2007
• Smad1 and Smad5 differentially regulate embryonic hematopoiesis..  110. 2007
• T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin..  110. 2007
• Homocysteine inhibits endothelial cell growth via DNA hypomethylation of the cyclin A gene..  110. 2007
• Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP)..  110. 2007
• Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia..  110. 2007
• Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts..  110. 2007
• Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis..  110. 2007
• OX40 costimulation turns off Foxp3+ Tregs..  110. 2007
• Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease..  110. 2007
• BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms..  110. 2007
• Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury..  110. 2007
• Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma..  110. 2007
• Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita..  110. 2007
• NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma..  110. 2007
• Hyperacute GVHD: risk factors, outcomes, and clinical implications..  109. 2007
• Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways..  109. 2007
• Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin..  109. 2007
• The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells..  109. 2007
• Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase..  109. 2007
• Pre-TCR expression cooperates with TEL-JAK2 to transform immature thymocytes and induce T-cell leukemia..  109. 2006
• Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis..  109. 2006
• Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy..  109. 2006
• A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies..  109. 2006
• ATM deficiency disrupts Tcra locus integrity and the maturation of CD4+CD8+ thymocytes..  109. 2006
• Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes..  109. 2006
• Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5..  109. 2006
• Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study..  109. 2006
• Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)..  109. 2006
• Deletion of tetraspanin Cd151 results in decreased pathologic angiogenesis in vivo and in vitro..  109. 2006
• Dendritic-cell maturation alters intracellular signaling networks, enabling differential effects of IFN-alpha/beta on antigen cross-presentation..  109. 2006
• PI3K regulates pleckstrin-2 in T-cell cytoskeletal reorganization..  109. 2006
• ADAP is required for normal alphaIIbbeta3 activation by VWF/GP Ib-IX-V and other agonists..  109. 2006
• A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study..  109. 2006
• Smad1 expands the hemangioblast population within a limited developmental window..  109. 2006
• Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group..  109. 2006
• The actin cloud induced by LFA-1-mediated outside-in signals lowers the threshold for T-cell activation..  109. 2006
• Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL..  109. 2006
• A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg?.  109. 2006
• Acanthocytes..  108. 2006
• Umbilical cord blood transplantation and cytomegalovirus: Posttransplantation infection and donor screening..  108. 2006
• Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells..  108. 2006
• MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients..  108. 2006
• STAT5 acts as a repressor to regulate early embryonic erythropoiesis..  108. 2006
• Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)..  108. 2006
• JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model..  108. 2006
• Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation..  108. 2006
• Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants..  108. 2006
• Correction of a murine model of von Willebrand disease by gene transfer..  108. 2006
• Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure..  108. 2006
• Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications..  108. 2006
• Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome..  107. 2006
• Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model..  107. 2006
• Foxp3+CD4+CD25+ T cells control virus-specific memory T cells in chimpanzees that recovered from hepatitis C..  107. 2006
• BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML..  107. 2006
• X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis..  107. 2006
• Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas..  107. 2006
• NF-kappaB is essential for the progression of KSHV- and EBV-infected lymphomas in vivo..  107. 2005
• Expansion of CD1d-restricted NKT cells in patients with primary HIV-1 infection treated with interleukin-2..  107. 2005
• Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD..  107. 2005
• A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia..  107. 2005
• Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha..  107. 2005
• Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura..  107. 2005
• Array comparative genomic hybridization reveals genomic copy number changes associated with outcome in diffuse large B-cell lymphomas..  107. 2005
• Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance..  107. 2005
• Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma..  107. 2005
• Remodeling specific immunity by use of MHC tetramers: demonstration in a graft-versus-host disease model..  107. 2005
• Antimyeloma activity of heat shock protein-90 inhibition..  107. 2005
• Monocytes form a vascular barrier and participate in vessel repair after brain injury..  107. 2005
• Coordination between NF-kappaB family members p50 and p52 is essential for mediating LTbetaR signals in the development and organization of secondary lymphoid tissues..  107. 2005
• Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas..  107. 2005
• Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation..  107. 2005
• Proangiogenic role of neutrophil-like inflammatory heterophils during neovascularization induced by growth factors and human tumor cells..  107. 2005
• KSHV G protein-coupled receptor inhibits lytic gene transcription in primary-effusion lymphoma cells via p21-mediated inhibition of Cdk2..  107. 2005
• p130Cas mediates the transforming properties of the anaplastic lymphoma kinase..  106. 2005
• Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL..  106. 2005
• The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia..  106. 2005
• Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation..  106. 2005
• CCR2 is required for CD8-induced graft-versus-host disease..  106. 2005
• A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation..  106. 2005
• The expression and the regulatory role of OX40 and 4-1BB heterodimer in activated human T cells..  106. 2005
• Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders..  106. 2005
• Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010..  106. 2005
• Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C..  106. 2005
• The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes..  106. 2005
• Tie2 activation contributes to hemangiogenic regeneration after myelosuppression..  106. 2005
• Rhabdomyosarcoma..  105. 2005
• Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab..  105. 2005
• Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes..  105. 2005
• Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study..  105. 2005
• The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells..  105. 2005
• Nanomolar concentration of NSC606985, a camptothecin analog, induces leukemic-cell apoptosis through protein kinase Cdelta-dependent mechanisms..  105. 2005
• A neurotrophin axis in myeloma: TrkB and BDNF promote tumor-cell survival..  105. 2005
• PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia..  105. 2005
• Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM)..  105. 2004
• Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy..  105. 2004
• Donor CD4+CD25+ T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation..  105. 2004
• Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy..  105. 2004
• A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor..  105. 2004
• Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment..  105. 2004
• Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cells..  105. 2004
• Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model..  105. 2004
• Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease..  104. 2004
• Expansion of CD7(low) and CD7(negative) CD8 T-cell effector subsets in HIV-1 infection: correlation with antigenic load and reversion by antiretroviral treatment..  104. 2004
• Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry..  104. 2004
• Atypical marginal zone hyperplasia of mucosa-associated lymphoid tissue: a reactive condition of childhood showing immunoglobulin lambda light-chain restriction..  104. 2004
• Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome..  104. 2004
• The small GTPase Rac1 links the Kaposi sarcoma-associated herpesvirus vGPCR to cytokine secretion and paracrine neoplasia..  104. 2004
• Targeted deletion of T-cell clones using alpha-emitting suicide MHC tetramers..  104. 2004
• Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation..  104. 2004
• Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS..  104. 2004
• Tumor necrosis factor-alpha blockade for the treatment of acute GVHD..  104. 2004
• The Flt3 internal tandem duplication mutant inhibits the function of transcriptional repressors by blocking interactions with SMRT..  103. 2004
• Infection of mature monocyte-derived dendritic cells with human cytomegalovirus inhibits stimulation of T-cell proliferation via the release of soluble CD83..  103. 2004
• Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma..  103. 2004
• Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: donor type matters..  103. 2004
• Germline mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia..  103. 2004
• Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133..  103. 2003
• Mutations of the PML tumor suppressor gene in acute promyelocytic leukemia..  103. 2003
• Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas..  103. 2003
• ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein..  103. 2003
• Presence of functional dendritic cells in patients chronically infected with hepatitis C virus..  103. 2003
• Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate..  103. 2003
• A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia..  103. 2003
• Annexin II mediates plasminogen-dependent matrix invasion by human monocytes: enhanced expression by macrophages..  103. 2003
• Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma..  103. 2003
• IL-10 regulates plasmacytoid dendritic cell response to CpG-containing immunostimulatory sequences..  102. 2003
• In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines..  103. 2003
• Does Helicobater pylori initiate or perpetuate immune thrombocytopenic purpura?.  103. 2003
• Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma..  103. 2003
• Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma..  102. 2003
• Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors..  102. 2003
• Primitive erythropoiesis is regulated by Smad-dependent signaling in postgastrulation mesoderm..  102. 2003
• Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years..  102. 2003
• The scavenger receptor MARCO mediates cytoskeleton rearrangements in dendritic cells and microglia..  102. 2003
• Green fluorescent protein selectively induces HSP70-mediated up-regulation of COX-2 expression in endothelial cells..  102. 2003
• Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele..  102. 2003
• Mechanisms of donor-specific transfusion tolerance: preemptive induction of clonal T-cell exhaustion via indirect presentation..  102. 2003
• Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning..  102. 2003
• 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials..  102. 2003
• RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement..  102. 2003
• Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma..  102. 2003
• Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H pylori in gastric MALT lymphoma..  102. 2003
• Coincident expression of the chemokine receptors CCR6 and CCR7 by pathologic Langerhans cells in Langerhans cell histiocytosis..  101. 2003
• High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia..  101. 2003
• Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial..  101. 2003
• Complement receptor 1 inhibitors for prevention of immune-mediated red cell destruction: potential use in transfusion therapy..  101. 2003
• Beta 2-microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells..  101. 2003
• Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts..  101. 2003
• Hyperhomocysteinemia accelerates atherosclerosis in cystathionine beta-synthase and apolipoprotein E double knock-out mice with and without dietary perturbation..  101. 2002
• A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer..  101. 2002
• A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma..  101. 2002
• High incidence of t(11;18)(q21;q21) in Helicobacter pylori-negative gastric MALT lymphoma..  101. 2002
• Fibroblast growth factor receptor-1 is expressed by endothelial progenitor cells..  100. 2002
• NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors..  101. 2002
• KSHV- and EBV-associated germinotropic lymphoproliferative disorder..  100. 2002
• Regulation of thymic epithelium by keratinocyte growth factor..  100. 2002
• Rituximab in the treatment of acquired factor VIII inhibitors..  100. 2002
• BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90..  100. 2002
• Expression of Skp2, a p27(Kip1) ubiquitin ligase, in malignant lymphoma: correlation with p27(Kip1) and proliferation index..  100. 2002
• Role of the adapter protein SLP-76 in GPVI-dependent platelet procoagulant responses to collagen..  100. 2002
• Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation..  101. 2002
• A 20-year perspective on the International Fanconi Anemia Registry (IFAR)..  101. 2002
• V(D)J recombinatorial repertoire diversification during intraclonal pro-B to B-cell differentiation..  101. 2002
• A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias..  100. 2002
• Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations..  100. 2002
• A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies..  100. 2002
• Efficacious immunomodulatory activity of the chemokine stromal cell-derived factor 1 (SDF-1): local secretion of SDF-1 at the tumor site serves as T-cell chemoattractant and mediates T-cell-dependent antitumor responses..  100. 2002
• Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia..  100. 2002
• The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML..  100. 2002
• Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival..  100. 2002
• Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation..  100. 2002
• Targeted alpha particle immunotherapy for myeloid leukemia..  100. 2002
• VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells..  101. 2002
• Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience..  100. 2002
• Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse..  100. 2002
• Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213..  100. 2002
• Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease..  100. 2002
• The spleen is a major site of megakaryopoiesis following transplantation of murine hematopoietic stem cells..  100. 2002
• Heme oxygenase-1-derived carbon monoxide is an autocrine inhibitor of vascular smooth muscle cell growth..  99. 2002
• Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study..  99. 2002
• Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation..  99. 2002
• Vaccination with CD20 peptides induces a biologically active, specific immune response in mice..  99. 2002
• Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy..  99. 2002
• A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease..  99. 2002
• Retinoid signaling regulates primitive (yolk sac) hematopoiesis..  99. 2002
• Spectral karyotyping identifies new rearrangements, translocations, and clinical associations in diffuse large B-cell lymphoma..  99. 2002
• VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition..  99. 2002
• Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia..  99. 2002
• Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy?.  99. 2002
• Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study..  99. 2002
• Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene..  99. 2002
• Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program..  99. 2002
• Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy..  99. 2002
• Quantitation, selection, and functional characterization of Epstein-Barr virus-specific and alloreactive T cells detected by intracellular interferon-gamma production and growth of cytotoxic precursors..  99. 2002
• Cyclin A transcriptional suppression is the major mechanism mediating homocysteine-induced endothelial cell growth inhibition..  99. 2002
• Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10..  99. 2002
• A rheostatic mechanism for T-cell inhibition based on elevation of activation thresholds..  98. 2001
• Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality..  98. 2001
• C-terminal peptide of thrombospondin-1 induces platelet aggregation through the Fc receptor gamma-chain-associated signaling pathway and by agglutination..  98. 2001
• Identification of poor prognostic features among patients requiring mechanical ventilation after hematopoietic stem cell transplantation..  98. 2001
• The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase..  98. 2001
• Survival of leukemic B cells promoted by engagement of the antigen receptor..  98. 2001
• Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia..  98. 2001
• Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells..  98. 2001
• Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease..  98. 2001
• Chronic graft-versus-host disease after allogeneic blood stem cell transplantation..  98. 2001
• T(11;18)(q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphoma that expresses nuclear BCL10..  98. 2001
• MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes..  97. 2001
• Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells..  97. 2001
• Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis..  97. 2001
• Growth factor-induced angiogenesis in vivo requires specific cleavage of fibrillar type I collagen..  97. 2001
• The combination of chemotherapy and systemic immunotherapy with soluble B7-immunoglobulin G leads to cure of murine leukemia and lymphoma and demonstration of tumor-specific memory responses..  97. 2001
• Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol..  97. 2001
• Expression of tumor-suppressor genes interferon regulatory factor 1 and death-associated protein kinase in primitive acute myelogenous leukemia cells..  97. 2001
• Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia..  97. 2001
• Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells..  97. 2001
• A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model..  97. 2001
• Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation..  97. 2001
• Plasminogen-mediated matrix invasion and degradation by macrophages is dependent on surface expression of annexin II..  97. 2001
• BCL-6 protein is expressed in precursor T-cell lymphoblastic lymphoma and in prenatal and postnatal thymus..  97. 2001
• Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes..  97. 2001
• Identification of alloreactive T-cell epitopes on the Rhesus D protein..  96. 2000
• Stable in vivo expression of glucose-6-phosphate dehydrogenase (G6PD) and rescue of G6PD deficiency in stem cells by gene transfer..  96. 2000
• Stromal-derived factor 1-induced megakaryocyte migration and platelet production is dependent on matrix metalloproteinases..  96. 2000
• AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein..  96. 2000
• High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis..  96. 2000
• Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells..  96. 2000
• Interleukin-9 enhances interleukin-5 receptor expression, differentiation, and survival of human eosinophils..  96. 2000
• Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis..  96. 2000
• Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: relationships to disease severity and bone marrow pathology..  96. 2000
• Wild-type HFE protein normalizes transferrin iron accumulation in macrophages from subjects with hereditary hemochromatosis..  96. 2000
• Adenoviral vector-mediated gene transfer to primitive human hematopoietic progenitor cells: assessment of transduction and toxicity in long-term culture..  96. 2000
• Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors..  96. 2000
• Rapid selection of antigen-specific T lymphocytes by retroviral transduction..  96. 2000
• BCL10 gene mutation in lymphoma..  95. 2000
• Longitudinal monitoring of immune reconstitution by CDR3 size spectratyping after T-cell-depleted allogeneic bone marrow transplant and the effect of donor lymphocyte infusions on T-cell repertoire..  95. 2000
• T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities..  95. 2000
• MUC1 dysregulation as the consequence of a t(1;14)(q21;q32) translocation in an extranodal lymphoma..  95. 2000
• Granulocyte-macrophage colony-stimulating factor stimulation results in phosphorylation of cAMP response element-binding protein through activation of pp90RSK..  95. 2000
• Human natural killer T cells acquire a memory-activated phenotype before birth..  95. 2000
• Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses..  95. 2000
• Stem cell transplantation in patients with severe congenital neutropenia without evidence of leukemic transformation..  95. 2000
• Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions..  95. 2000
• Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors..  95. 2000
• Protein truncation test of LYST reveals heterogenous mutations in patients with Chediak-Higashi syndrome..  95. 2000
• Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: an analysis from the international bone marrow transplant registry..  95. 2000
• Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma..  95. 2000
• Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease..  95. 2000
• Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: a report from the children's cancer group..  94. 1999
• Stromal derived factor-1-induced chemokinesis of cord blood CD34(+) cells (long-term culture-initiating cells) through endothelial cells is mediated by E-selectin..  94. 1999
• Vaccines with interleukin-12-transduced acute myeloid leukemia cells elicit very potent therapeutic and long-lasting protective immunity..  94. 1999
• A novel BTB/POZ transcriptional repressor protein interacts with the Fanconi anemia group C protein and PLZF..  94. 1999
• Enhanced liver uptake of opsonized red blood cells after in vivo transfer of FcgammaRIIA cDNA to the liver..  94. 1999
• The W(sh), W(57), and Ph Kit expression mutations define tissue-specific control elements located between -23 and -154 kb upstream of Kit..  94. 1999
• Association of chromosome arm 9p abnormalities with adverse risk in childhood acute lymphoblastic leukemia: A report from the Children's Cancer Group..  94. 1999
• Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation..  94. 1999
• C/EBPalpha bypasses granulocyte colony-stimulating factor signals to rapidly induce PU.1 gene expression, stimulate granulocytic differentiation, and limit proliferation in 32D cl3 myeloblasts..  94. 1999
• Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia..  93. 1999
• E1(-)E4(+) adenoviral gene transfer vectors function as a "pro-life" signal to promote survival of primary human endothelial cells..  93. 1999
• A novel SH2-containing phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase (SHIP2) is constitutively tyrosine phosphorylated and associated with src homologous and collagen gene (SHC) in chronic myelogenous leukemia progenitor cells..  93. 1999
• Nonimmunoglobulin gene hypermutation in germinal center B cells..  93. 1999
• Downregulation of interleukin-12 (IL-12) responsiveness in human T cells by transforming growth factor-beta: relationship with IL-12 signaling..  93. 1999
• Enhanced endothelial cell apoptosis in splenic tissues of patients with thrombotic thrombocytopenic purpura..  93. 1999
• Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions..  93. 1999
• Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients..  93. 1999
• Selective expansion of alveolar macrophages in vivo by adenovirus-mediated transfer of the murine granulocyte-macrophage colony-stimulating factor cDNA..  93. 1999
• DNA typing for HLA-A and HLA-B identifies disparities between patients and unrelated donors matched by HLA-A and HLA-B serology and HLA-DRB1..  93. 1999
• Mcl-1 in transgenic mice promotes survival in a spectrum of hematopoietic cell types and immortalization in the myeloid lineage..  92. 1998
• A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia..  92. 1998
• BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome..  92. 1998
• Allogeneic bone marrow transplantation for low-grade lymphoma..  92. 1998
• Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a "lupus procoagulant" phenomenon..  92. 1998
• Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner..  92. 1998
• SLP-76-Cbl-Grb2-Shc interactions in FcgammaRI signaling..  92. 1998
• Targeted inactivation of murine band 3 (AE1) gene produces a hypercoagulable state causing widespread thrombosis in vivo..  92. 1998
• Clinical significance of MLL-AF4 fusion transcript expression in the absence of a cytogenetically detectable t(4;11)(q21;q23) chromosomal translocation..  92. 1998
• Intermittent, repetitive corticosteroid-induced upregulation of platelet levels after adenovirus-mediated transfer to the liver of a chimeric glucocorticoid-responsive promoter controlling the thrombopoietin cDNA..  92. 1998
• Blood dendritic cells from myeloma patients are not infected with Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8)..  92. 1998
• Cytosine deaminase adenoviral vector and 5-fluorocytosine selectively reduce breast cancer cells 1 million-fold when they contaminate hematopoietic cells: a potential purging method for autologous transplantation..  92. 1998
• Evidence for circulating bone marrow-derived endothelial cells..  92. 1998
• Chromosomal and gene amplification in diffuse large B-cell lymphoma..  92. 1998
• Interleukin-6-induced inhibition of multiple myeloma cell apoptosis: support for the hypothesis that protection is mediated via inhibition of the JNK/SAPK pathway..  92. 1998
• Follicular lymphomas contain a clonally linked but phenotypically distinct neoplastic B-cell population in the interfollicular zone..  91. 1998
• Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma..  91. 1998
• The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1..  91. 1998
• Demonstration of Kaposi's sarcoma-associated herpes virus cyclin D homolog in cutaneous Kaposi's sarcoma by colorimetric in situ hybridization using a catalyzed signal amplification system..  91. 1998
• Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia..  91. 1998
• Chronic lymphocytic leukemia B cells can express CD40 ligand and demonstrate T-cell type costimulatory capacity..  91. 1998
• High-efficiency gene transfer into ex vivo expanded human hematopoietic progenitors and precursor cells by adenovirus vectors..  91. 1998
• Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses..  91. 1998
• Complete deficiency of glycophorin A in red blood cells from mice with targeted inactivation of the band 3 (AE1) gene..  91. 1998
• Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma..  91. 1998
• Expression of granulocyte-macrophage colony-stimulating factor receptors in human prostate cancer..  91. 1998
• Involvement of interleukin-3 in delayed-type hypersensitivity..  91. 1998
• T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease..  91. 1998
• A naturally occurring mutation in Fc gamma RIIA: a Q to K127 change confers unique IgG binding properties to the R131 allelic form of the receptor..  91. 1998
• Activation of human platelets by the membrane-expressed A1 domain of von Willebrand factor..  90. 1997
• Preferential dissemination of B-cell gastric mucosa-associated lymphoid tissue (MALT) lymphoma to the splenic marginal zone..  90. 1997
• Anti-CD43 inhibits monocyte-endothelial adhesion in inflammation and atherogenesis..  90. 1997
• Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production..  90. 1997
• Retrovirally transduced human dendritic cells express a normal phenotype and potent T-cell stimulatory capacity..  90. 1997
• Functional interactions between the thrombin receptor and the T-cell antigen receptor in human T-cell lines..  90. 1997
• Myeloma bone marrow plasma cells: evidence for their capacity as antigen-presenting cells..  90. 1997
• Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8..  90. 1997
• Recombinant retroviruses pseudotyped with the vesicular stomatitis virus G glycoprotein mediate both stable gene transfer and pseudotransduction in human peripheral blood lymphocytes..  90. 1997
• Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines..  90. 1997
• Characterization of the underlying molecular defect in hereditary spherocytosis associated with spectrin deficiency..  90. 1997
• Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: a report from the Children's Cancer Group..  90. 1997
• Defensin stimulates the binding of lipoprotein (a) to human vascular endothelial and smooth muscle cells..  89. 1997
• Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy..  89. 1997
• Cellular expression of antiapoptotic BCL-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: a Children's Cancer Group Study..  89. 1997
• Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients..  89. 1997
• Strict lymphotropism of Epstein-Barr virus during acute infectious mononucleosis in nonimmunocompromised individuals..  89. 1997
• Clinical features and treatment outcome of children with biphenotypic CD2+ CD19+ acute lymphoblastic leukemia: a Children's Cancer Group study..  89. 1997
• Molecular characterization of IgA- and/or IgG-switched chronic lymphocytic leukemia B cells..  89. 1997
• Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells..  89. 1997
• A murine model for human cord blood transplantation: near-term fetal and neonatal peripheral blood cells can achieve long-term bone marrow engraftment in sublethally irradiated adult recipients..  89. 1997
• Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression..  89. 1997
• Microsatellite instability is rare in B-cell non-Hodgkin's lymphomas..  89. 1997
• Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions..  89. 1997
• Transendothelial migration of CD34+ and mature hematopoietic cells: an in vitro study using a human bone marrow endothelial cell line..  89. 1997
• Lovastatin inhibits T-cell antigen receptor signaling independent of its effects on ras..  88. 1996
• CD2 antigen expression on leukemic cells as a predictor of event-free survival after chemotherapy for T-lineage acute lymphoblastic leukemia: a Children's Cancer Group study..  88. 1996
• Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation..  88. 1996
• Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translocated Bcl-2 gene..  88. 1996
• p21/WAF1 cyclin-kinase inhibitor expression in non-Hodgkin's lymphomas: a potential marker of p53 tumor-suppressor gene function..  88. 1996
• Differential mechanisms in the regulation of endogenous levels of thrombopoietin and interleukin-11 during thrombocytopenia: insight into the regulation of platelet production..  88. 1996
• Growth pattern and clinical correlation of subcutaneously inoculated human primary acute leukemias in severe combined immunodeficiency mice..  88. 1996
• Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus..  88. 1996
• CD4+ T-cell induction of Fas-mediated apoptosis in Burkitt's lymphoma B cells..  88. 1996
• Detection of maternal DNA in placental/umbilical cord blood by locus-specific amplification of the noninherited maternal HLA gene..  88. 1996
• In vivo adenovirus vector-mediated transfer of the human thrombopoietin cDNA maintains platelet levels during radiation-and chemotherapy-induced bone marrow suppression..  88. 1996
• Tumor necrosis factor-alpha induces activation of coagulation and fibrinolysis in baboons through an exclusive effect on the p55 receptor..  88. 1996
• Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus..  88. 1996
• Activation of MAP kinase-activated protein kinase 2 in human neutrophils after phorbol ester or fMLP peptide stimulation..  87. 1996
• Kaposi's sarcoma-associated herpesvirus (KSHV or HHV8) in primary effusion lymphoma: ultrastructural demonstration of herpesvirus in lymphoma cells..  87. 1996
• Dendritic cells and macrophages can mature independently from a human bone marrow-derived, post-colony-forming unit intermediate..  87. 1996
• The p53 gene in pediatric therapy-related leukemia and myelodysplasia..  87. 1996
• Specific human cellular immunity to bcr-abl oncogene-derived peptides..  87. 1996
• Plasma from patients with idiopathic and human immunodeficiency virus-associated thrombotic thrombocytopenic purpura induces apoptosis in microvascular endothelial cells..  87. 1996
• The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation..  87. 1996
• Deficiency of the Hck and Src tyrosine kinases results in extreme levels of extramedullary hematopoiesis..  87. 1996
• Intracellular calcium and calcineurin regulate neutrophil motility on vitronectin through a receptor identified by antibodies to integrins alphav and beta3..  87. 1996
• Fas ligation induces apoptosis and Jun kinase activation independently of CD45 and Lck in human T cells..  87. 1996
• Molecular characterization of the t(2;5) (p23; q35) translocation in anaplastic large cell lymphoma (Ki-1) and Hodgkin's disease..  87. 1996
• REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma..  87. 1996
• Granulocyte colony-stimulating factor rapidly activates a distinct STAT-like protein in normal myeloid cells..  86. 1995
• CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation..  86. 1995
• Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac..  86. 1995
• Human bone marrow microvascular endothelial cells support long-term proliferation and differentiation of myeloid and megakaryocytic progenitors..  86. 1995
• Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies..  86. 1995
• p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32)..  86. 1995
• Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease..  86. 1995
• In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences..  86. 1995
• Del (7)(q32) is associated with a subset of small lymphocytic lymphoma with plasmacytoid features..  86. 1995
• Expression of bcl-xL can confer a multidrug resistance phenotype..  86. 1995
• Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease..  86. 1995
• Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations..  86. 1995
• Cytokine loops involving interferon-gamma and IP-10, a cytokine chemotactic for CD4+ lymphocytes: an explanation for the epidermotropism of cutaneous T-cell lymphoma?.  86. 1995
• Growth in children after bone marrow transplantation for acute leukemia..  86. 1995
• BCL-6 protein is expressed in germinal-center B cells..  86. 1995
• 9-cis retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia..  85. 1995
• High-molecular-weight kininogen is exclusively membrane bound on endothelial cells to influence activation of vascular endothelium..  85. 1995
• Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells..  85. 1995
• Selective treatment of SCID mice bearing methotrexate-transport-resistant human acute lymphoblastic leukemia tumors with trimetrexate and leucovorin protection..  85. 1995
• Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules..  85. 1995
• Platelet adhesion and aggregation on human type VI collagen surfaces under physiological flow conditions..  85. 1995
• Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts..  85. 1995
• Posttransplantation lymphoproliferative disorders frequently contain type A and not type B Epstein-Barr virus..  85. 1995
• Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders..  85. 1995
• Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial..  85. 1995
• Optimization of conditions for ex vivo expansion of CD34+ cells from patients with stage IV breast cancer..  84. 1994
• Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia..  84. 1994
• Stimulation of erythropoiesis by in vivo gene therapy: physiologic consequences of transfer of the human erythropoietin gene to experimental animals using an adenovirus vector..  84. 1994
• Granulocyte colony-stimulating factor (CSF) but not interleukin-1 (IL-1), IL-3, and granulocyte-macrophage CSF protect bone marrow progenitor cells from suppression by allosensitized cytotoxic T cells..  84. 1994
• Phenotypic and functional characterization of T-BAM (CD40 ligand)+ T-cell non-Hodgkin's lymphoma..  84. 1994
• Rearrangements of the BCL-6 gene in acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma: association with diffuse large-cell subtype..  84. 1994
• Isolation and characterization of human bone marrow microvascular endothelial cells: hematopoietic progenitor cell adhesion..  84. 1994
• Molecular characterization of CD30+ anaplastic large-cell lymphoma: high frequency of c-myc proto-oncogene activation..  83. 1994
• Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia..  83. 1994
• Two acquired immunodeficiency syndrome-associated Burkitt's lymphomas produce specific anti-i IgM cold agglutinins using somatically mutated VH4-21 segments..  83. 1994
• Clinical and morphologic features of B-cell small lymphocytic lymphoma with del(6)(q21q23)..  83. 1994
• Cytogenetic features of infants less than 12 months of age at diagnosis of acute lymphoblastic leukemia: impact of the 11q23 breakpoint on outcome: a report of the Childrens Cancer Group..  83. 1994
• Involvement of the sphingomyelin pathway in autocrine tumor necrosis factor signaling for human immunodeficiency virus production in chronically infected HL-60 cells..  83. 1994
• A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity..  83. 1994
• Platelets inhibit the induction of nitric oxide synthesis by interleukin-1 beta in vascular smooth muscle cells..  83. 1994
• Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma..  83. 1994
• Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia..  83. 1994
• Molecular genetic demonstration of the diverse evolution of Richter's syndrome (chronic lymphocytic leukemia and subsequent large cell lymphoma)..  83. 1994
• Isolation and characterization of a TATA-less promoter for the human beta 3 integrin gene..  83. 1994
• Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor-alpha and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma..  83. 1994
• Additive effect of erythropoietin and heme on murine hematopoietic recovery after azidothymidine treatment..  82. 1993
• Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma..  82. 1993
• p53 mutations are associated with histologic transformation of follicular lymphoma..  82. 1993
• 6q deletions define distinct clinico-pathologic subsets of non-Hodgkin's lymphoma..  82. 1993
• Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase..  82. 1993
• Treatment of Diamond-Blackfan anemia with recombinant human interleukin-3..  82. 1993
• Recombinant human leukemia inhibitory factor induces acute phase proteins and raises the blood platelet counts in nonhuman primates..  81. 1993
• High-dose UV-B radiation alters human dendritic cell costimulatory activity but does not allow dendritic cells to tolerize T lymphocytes to alloantigen in vitro..  81. 1993
• A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia..  81. 1993
• Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias..  81. 1993
• Interleukin-1 modulation of cytokine receptors on human neutrophils: in vitro and in vivo studies..  81. 1993
• Lasting safe interruption of endarterectomy thrombosis by transiently infused antithrombin peptide D-Phe-Pro-ArgCH2Cl in baboons..  81. 1993
• Identification of BCR/ABL-negative primitive hematopoietic progenitor cells within chronic myeloid leukemia marrow..  81. 1993
• Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma..  81. 1993
• Effect of stem cell factor on in vitro erythropoiesis in patients with bone marrow failure syndromes..  80. 1992
• Myeloid and lymphoid chimerism after T-cell-depleted bone marrow transplantation: evaluation of conditioning regimens using the polymerase chain reaction to amplify human minisatellite regions of genomic DNA..  80. 1992
• Structural and functional analysis of oncogenes and tumor suppressor genes in adult T-cell leukemia/lymphoma shows frequent p53 mutations..  80. 1992
• Determination of the DNA content of the Reed-Sternberg cell of Hodgkin's disease by image analysis..  80. 1992
• t(9;14)(p13;q32) denotes a subset of low-grade non-Hodgkin's lymphoma with plasmacytoid differentiation..  80. 1992
• Glutathione depletion in chronic lymphocytic leukemia B lymphocytes..  80. 1992
• Deletions involving two distinct regions of 6q in B-cell non-Hodgkin lymphoma..  80. 1992
• Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia..  80. 1992
• Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells..  79. 1992
• Long-term generation of colony-forming cells in liquid culture of CD34+ cord blood cells in the presence of recombinant human stem cell factor..  79. 1992
• Transcriptional and posttranscriptional modulation of human neutrophil elastase gene expression..  79. 1992
• Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease..  79. 1992
• Constitutive expression of p53 protein in enriched normal human marrow blast cell populations..  79. 1992
• Follicular lymphoma with t(8;14)(q24;q32): a distinct clinical and molecular subset of t(8;14)-bearing lymphomas..  79. 1992
• Propagation of human blastic myeloid leukemias in the SCID mouse..  79. 1992
• Heme oxygenase is a positive acute-phase reactant in human Hep3B hepatoma cells..  79. 1992
• High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia..  79. 1992
• Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia..  79. 1992
• Effect of recombinant human growth hormone on acute and chronic human immunodeficiency virus infection in vitro..  79. 1992
• Endothelium-derived relaxing factor inhibits thrombin-induced platelet aggregation by inhibiting platelet phospholipase C..  79. 1992
• Transfer of specific immunity to B-cell lymphoma with syngeneic bone marrow in mice: a strategy for using autologous marrow as an anti-tumor therapy..  78. 1991
• A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer..  78. 1991
• Autoantibody-associated cross-reactive idiotype-bearing human B lymphocytes: distribution and characterization, including Ig VH gene and CD5 antigen expression..  78. 1991
• Enhanced detection of the t(14;18) translocation in malignant lymphoma using pulsed-field gel electrophoresis..  78. 1991
• Activation of platelet heparitinase by tumor cell-derived factors..  78. 1991
• Human neutrophils express the alpha 1-antitrypsin gene and produce alpha 1-antitrypsin..  77. 1991
• Detection and characterization of human T-cell lymphotropic virus type I (HTLV-I) associated T-cell neoplasms in an HTLV-I nonendemic region by polymerase chain reaction..  77. 1991
• Purification and partial characterization of a human hematopoietic precursor population..  77. 1991
• Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect..  77. 1991
• Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination..  77. 1991
• Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia..  77. 1991
• Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: clinical correlations..  77. 1991
• Epstein-Barr virus infection precedes clonal expansion in Burkitt's and acquired immunodeficiency syndrome-associated lymphoma..  77. 1991
• MYC rearrangement and translocations involving band 8q24 in diffuse large cell lymphomas..  77. 1991
• Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype..  77. 1991
• Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: active immunization with tumor-derived idiotypic immunoglobulin..  76. 1990
• Parvovirus B19-induced perturbation of human megakaryocytopoiesis in vitro..  76. 1990
• B-cell differentiation following autologous, conventional, or T-cell depleted bone marrow transplantation: a recapitulation of normal B-cell ontogeny..  76. 1990
• Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease..  76. 1990
• A new treatment for polycythemia vera: recombinant interferon alfa..  76. 1990
• Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia..  75. 1990
• Effects of parenteral recombinant human macrophage colony-stimulating factor on monocyte number, phenotype, and antitumor cytotoxicity in nonhuman primates..  75. 1990
• Use of an anti-pan T-lymphocyte ricin a chain immunotoxin in steroid-resistant acute graft-versus-host disease..  75. 1990
• Cytogenetic analysis of chimerism and leukemia relapse in chronic myelogenous leukemia patients after T cell-depleted bone marrow transplantation..  75. 1990
• Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2a..  75. 1990
• Effect of tamoxifen on regulation of viral replication and human immunodeficiency virus (HIV) long terminal repeat-directed transcription in cells chronically infected with HIV-1..  75. 1990
• Delayed activation of quiescent donor hematopoietic stem cells in the host marrow cavity by anti-host monoclonal antibody..  74. 1989
• Increased density of ecto 5' nucleotidase antigen on leukemic T cells from patients with cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma..  74. 1989
• Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: I. Analysis of risk factors and results of secondary transplants..  74. 1989
• Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: II. In vitro analyses of host effector mechanisms..  74. 1989
• t(3;22)(q27;q11): a novel translocation associated with diffuse non-Hodgkin's lymphoma..  74. 1989
• Synergistic cytotoxic effect of azidothymidine and recombinant interferon alpha on normal human bone marrow progenitor cells..  74. 1989
• Inhibition of vascular endothelial cell prostacyclin synthesis by plasmin..  74. 1989
• Effects of interleukin-1 on hematopoietic progenitors: evidence of stimulatory and inhibitory activities in a primate model..  74. 1989
• Effect of glucocorticoids on chronic human immunodeficiency virus (HIV) infection and HIV promoter-mediated transcription..  74. 1989
• GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma..  73. 1989
• Correlation between interleukin-1 production and engraftment of transplanted bone marrow stem cells in patients with lethal immunodeficiencies..  73. 1989
• Extranodal noncutaneous lymphoid hyperplasias represent a continuous spectrum of B-cell neoplasia: demonstration by molecular genetic analysis..  73. 1989
• Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital..  73. 1989
• Immune reconstitution following bone marrow transplantation: comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts..  73. 1989
• PGE1 accelerates thrombolysis by tissue plasminogen activator..  73. 1989
• Beta-thalassemia due to two novel nucleotide substitutions in consensus acceptor splice sequences of the beta-globin gene..  73. 1989
• Respiratory burst in adherent human neutrophils: triggering by colony-stimulating factors CSF-GM and CSF-G..  73. 1989
• Down regulation of myelopoiesis by mediators inhibiting the production of macrophage-derived granulomonopoietic enhancing activity (GM-EA)..  72. 1988
• Differential expression of LFA-1 molecules in non-Hodgkin's lymphoma and lymphoid leukemia..  72. 1988
• Elimination of myeloma cells from bone marrow by using monoclonal antibodies and magnetic immunobeads..  72. 1988
• Frequent c-myc oncogene activation and infrequent presence of Epstein-Barr virus genome in AIDS-associated lymphoma..  72. 1988
• Maintenance treatment of adults with chronic refractory immune thrombocytopenic purpura using repeated intravenous infusions of gammaglobulin..  72. 1988
• Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia..  72. 1988
• High-dose cytosine arabinoside and fractionated total-body irradiation: an improved preparative regimen for bone marrow transplantation of children with acute lymphoblastic leukemia in remission..  71. 1988
• Human immunodeficiency virus infection in patients with leukemia..  71. 1988
• Host origin of the human hematopoietic microenvironment following allogeneic bone marrow transplantation..  70. 1987
• Interleukin 2-activated killer cells in patients following transplants of soybean lectin-separated and E rosette-depleted bone marrow..  70. 1987
• Immunoglobulin and T cell receptor beta chain gene rearrangement analysis of ocular adnexal lymphoid neoplasms: clinical and biologic implications..  70. 1987
• Interleukin-2 production and response to interleukin-2 by peripheral blood mononuclear cells from patients after bone marrow transplantation: II. Patients receiving soybean lectin-separated and T cell-depleted bone marrow..  70. 1987
• Localization of surface vWF on resting and stimulated platelets..  70. 1987
• T cell receptor (alpha, beta, gamma) gene rearrangements and expression in normal and leukemic large granular lymphocytes/natural killer cells..  70. 1987
• Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species..  70. 1987
• Intermediate- to high-grade histology of lymphomas carrying t(14;18) is associated with additional nonrandom chromosome changes..  70. 1987
• Photoradiation models for the clinical ex vivo treatment of autologous bone marrow grafts..  70. 1987
• Myeloablation with diaziquone: in vitro assessment..  69. 1987
• Activities of four purified growth factors on highly enriched human hematopoietic progenitor cells..  69. 1987
• Synergistic inhibition of platelet activation by plasmin and prostaglandin I2..  69. 1987
• Expression of two natural killer cell antigens, H-25 and H-366, by human immature myeloid cells and by erythroid and granulocytic/monocytic colony-forming units..  69. 1987
• Cytogenetic and histologic correlations in malignant lymphoma..  69. 1987
• Preclinical assessment of purging with VP-16-213: key role for long-term marrow cultures..  69. 1987
• Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease..  68. 1986
• Radiobiological properties of the human hematopoietic microenvironment: contrasting sensitivities of proliferative capacity and hematopoietic function to in vitro irradiation..  67. 1986
• Incorporation of platelet and leukocyte lipoxygenase metabolites by cultured vascular cells..  67. 1986
• Analysis of T-cell receptor beta chain (T beta) gene rearrangements demonstrates the monoclonal nature of T-cell chronic lymphoproliferative disorders..  67. 1986
• Incidence of involvement of the B and T lymphocyte lineages in chronic myelogenous leukemia..  66. 1985
• Platelet membrane topography: colocalization of thrombospondin and fibrinogen with the glycoprotein IIb-IIIa complex..  66. 1985
• Megakaryocyte interaction with subendothelial extracellular matrix is associated with adhesion, platelet-like shape change, and thromboxane A2 production..  66. 1985
• Specific antibody-blocking activities in antilymphocyte globulin as correlates of efficacy for the treatment of aplastic anemia..  66. 1985
• Constitutive production of leukemia differentiation, colony-stimulating, erythroid burst-promoting, and pluripoietic factors by a human hepatoma cell line: characterization of the leukemia differentiation factor..  66. 1985
• Platelet interaction with subendothelial extracellular matrix: platelet-fibrinogen interactions are essential for platelet aggregation but not for the matrix-induced release reaction..  65. 1985
• Biological characterization of a granulomonopoietic enhancing activity derived from cultured human lipid-containing macrophages..  65. 1985
• Depletion of stromal cell elements in human marrow grafts separated by soybean agglutinin..  65. 1985
• Effects of in vitro purging with 4-hydroperoxycyclophosphamide on the hematopoietic and microenvironmental elements of human bone marrow..  65. 1985
• Regulation of human peripheral blood erythroid burst-forming unit growth by T lymphocytes and T lymphocyte subpopulations defined by OKT4 and OKT8 monoclonal antibodies..  65. 1985
• Monocytes and macrophages synthesize and secrete thrombospondin..  65. 1985
• Preparation and characterization of monoclonal antibodies recognizing two distinct differentiation antigens (Pro-Im1, Pro-Im2) on early hematopoietic cells..  64. 1984
• Defective interleukin 2 production in patients after bone marrow transplantation and in vitro restoration of defective T lymphocyte proliferation by highly purified interleukin 2..  64. 1984
• Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by cancer and leukemia group B..  64. 1984
• Incidence of acute graft-versus-host disease with and without methotrexate prophylaxis in allogeneic bone marrow transplant patients..  64. 1984
• A randomized study of the efficacy of consolidation therapy in adult acute nonlymphocytic leukemia..  63. 1984
• Distribution of antigens defined by OKB monoclonal antibodies on benign and malignant lymphoid cells and on nonlymphoid tissues..  63. 1984
• Prognostic discrimination in "good-risk" chronic granulocytic leukemia..  63. 1984
• Allogeneic bone marrow transplantation for patients with acute nonlymphocytic leukemia..  63. 1984
• Human megakaryocytes. III. Characterization in myeloproliferative disorders..  63. 1984
• Primary therapy of acute promyelocytic leukemia: results of amsacrine- and daunorubicin-based therapy..  63. 1984
• Characterization of a monoclonal antibody that reacts with an activation antigen on human B cells: reactions on mitogen-stimulated blood lymphocytes and cells of normal lymph nodes..  62. 1983
• Histidine-rich glycoprotein is present in human platelets and is released following thrombin stimulation..  62. 1983
• Antithoracic duct lymphocyte globulin therapy of severe aplastic anemia..  62. 1983
• Allogeneic bone marrow transplantation for patients with acute lymphoblastic leukemia..  62. 1983
• Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura..  62. 1983
• Proliferative potential of subpopulations of granulocyte-macrophage progenitor cells in normal subjects and chronic myelogenous leukemia patients..  62. 1983
• A new human B-lymphocyte surface antigen (BL 2) detectable by a hybridoma monoclonal antibody: distribution on benign and malignant lymphoid cells..  62. 1983
• Prognostic significance of receptors for the third component of complement an heavy chain phenotype in diffuse B-cell lymphomas..  62. 1983
• Tin-protoporphyrin suppression of hyperbilirubinemia in mutant mice with severe hemolytic anemia..  61. 1983
• Association of cell cycle expression of Ia-like antigenic determinations on normal human multipotential (CFU-GEMM) and erythroid (BFU-E) progenitor cells with regulation in vitro by acidic isoferritins..  61. 1983
• Treatment of refractory adult lymphoblastic leukemia (ALL) with 4'(9-acridinylamino) methanesulfon-M-anisidide (AMSA)..  60. 1982
• Analysis of T-cell differentiation antigens in acute lymphatic leukemia using monoclonal antibodies..  60. 1982
• Electron microscopic localization of factor-VIII-related antigen in adult human blood vessels..  60. 1982
• Monocyte-macrophage-derived acidic isoferritins: normal feedback regulators of granulocyte-macrophage progenitor cells in vitro..  60. 1982
• Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study..  60. 1982
• Suppression of lymphocyte responses by monocytes with untreated and treated multiple myeloma..  60. 1982
• Characteristics of bone marrow fibroblast colony-forming cells (CFU-F) and their progeny in patients with myeloproliferative disorders..  59. 1982
• Growth characteristics of leukemic and normal hematopoietic cells in Ph' + chronic myelogenous leukemia and effects of intensive treatment..  59. 1982
• T-lymphocyte reconstitution in recipients of bone marrow transplants with and without GVHD: imbalances of T-cell subpopulations having unique regulatory and cognitive functions..  59. 1982
• Bone marrow cell count per cubic millimeter bone marrow: a new parameter for quantitating therapy-induced cytoreduction in acute leukemia..  59. 1982
• Enrichment for CFU-C from murine and human bone marrow using soybean agglutinin..  59. 1982
• Expression of Ia-antigens on normal and chronic myeloid leukemic human granulocyte-macrophage colony-forming cells (CFU-GM) is associated with the regulation of cell proliferation by prostaglandin E..  59. 1982
• Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B..  58. 1981
• Effects of acetyl glyceryl ether phosphorylcholine on human platelet function in vitro..  58. 1981
• Prostacyclin and beta-adrenergic catecholamines inhibit arachidonate release and PGI2 synthesis by vascular endothelium..  58. 1981
• Human megakaryocyte stimulation of proliferation of bone marrow fibroblasts..  57. 1981
• The significance of splenomegaly in 101 adults with acute lymphoblastic leukemia (ALL) at presentation and during remission..  57. 1981
• Reed-Sternberg cells in Hodgkin's disease contain fibronectin..  57. 1981
• Cytochemically demonstrable B-glucuronidase activity in normal and neoplastic human lymphoid cells..  56. 1980
• Characterization of B-cell leukemias: a tentative immunomorphological scheme..  56. 1980
• Regulation of platelet arachidonic acid oxygenation by cyclic AMP..  56. 1980
• Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny..  56. 1980
• Nodular histiocytic lymphoma: an aggressive nodular lymphoma with potential for prolonged disease-free survival..  56. 1980
• Localization of factor-VIII-related antigen in human vascular subendothelium..  55. 1980
• Continuous human bone marrow culture: Ia antigen characterization of probable pluripotential stem cells..  55. 1980
• Heterogeneity of cell lineages in L3 leukemias..  55. 1980
• Inhibition of platelet function by organic nitrate vasodilators..  55. 1980
• Ia antigen expression by human malignant lymphomas: correlation with conventional lymphoid markers..  55. 1980
• Discrimination of human leukemia subtypes by flow cytometric analysis of cellular DNA and RNA..  55. 1980
• Combination chemotherapy for terminal-phase chronic granulocytic leukemia: cancer and leukemia group B studies..  55. 1980
• Selective binding of the factor VIII/von Willebrand factor protein to human platelets..  55. 1980
• Results of treatment of Ph'+ chronic myelogenous leukemia with an intensive treatment regimen (L-5 protocol)..  53. 1979
• Platelet resistance to prostaglandin D2 in patients with myeloproliferative disorders..  52. 1978
• Role for monocyte-macrophage-derived colony-stimulating factor and prostaglandin E in the positive and negative feedback control of myeloid stem cell proliferation..  52. 1978
• Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia..  50. 1977
• In memoriam: Sam Granick 1909-1977..  50. 1977
• Inhibition of ristocetin-induced platelet agglutination by vancomycin..  50. 1977
• Cell marker analysis in acute monocytic leukemias..  49. 1977
• Migration of transfused granulocytes in leukopenic dogs..  49. 1977
• A clinical study of the lupus anticoagulant..  48. 1976
• Molecular and cellular effects of antisickling concentrations of alkylureas..  48. 1976
• Defective platelet function following the administration of penicillin compounds..  47. 1976
• Thrombotic thrombocytopenic purpura--coagulation parameters in twelve patients..  42. 1973
• The importance of bone marrow biopsy in the staging of patients with lymphosarcoma..  41. 1973
• Nature of the defect in congenital factor V deficiency: study in a patient with an acquired circulating anticoagulant..  39. 1972
• Inhibition of fibrin monomer polymerization by lambda myeloma globulins..  39. 1972
• Long-term effects of local irradiation of the marrow on erythron and red cell function..  36. 1970
• Leukemia in Fanconi's anemia: cytogenetic and tumor virus susceptibility studies..  36. 1970
• Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults..  32. 1968
• Characteristics of the terminal phase of chronic granulocytic leukemia..  32. 1968
• Platelet amino acid levels in essential thrombocytosis..  27. 1966
• Two Bence Jones proteins of different immunologic types in the same patient with multiple myeloma..  27. 1966
• IMMUNOLOGIC STUDIES OF PLATELET PROTEIN..  25. 1965
• USE OF TESTOSTERONE AND BUSULFAN IN THE TREATMENT OF MYELOFIBROSIS WITH MYELOID METAPLASIA..  23. 1964
• A comparative study of two regimens of combination chemotherapy in acute leukemia..  13. 1958
• The role of the mature neutrophil in bacterial infections in acute leukemia..  12. 1957
• Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3..  135. 2020
• Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients..  132. 2018
• Increased risk of colon cancer and osteogenic sarcoma in Diamond-Blackfan anemia..  132. 2018
• Eltrombopag mobilizes iron in patients with aplastic anemia..  131. 2018
• Patients treated with oxaliplatin are at risk for thrombocytopenia caused by multiple drug-dependent antibodies..  131. 2018
• Erdheim-Chester disease: the "targeted" revolution..  130. 2017
• Plasmin regulation of acute cytokine storm..  130. 2017
• HIV multicentric Castleman: rituximab sans maintenance..  129. 2017
• Modeling CBL activating mutations in vivo..  129. 2017
• Immune reconstitution and remission in CML..  129. 2017
• Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis..  129. 2017
• Down for the count in acute myeloid leukemia..  128. 2016
• Anakinra as efficacious therapy for 2 cases of intracranial Erdheim-Chester disease..  128. 2016
• To B or not to B maintained?.  128. 2016
• VWF, ADAMTS13, and acute coronary syndromes..  127. 2016
• Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma..  127. 2016
• Is the open mouth mightier than the needle?.  126. 2015
• How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses..  126. 2015
• mTOR inhibition in T-cell lymphoma: a path(way) forward..  126. 2015
• Life, genes, and death in Ph- MPNs..  124. 2014
• Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event..  123. 2014
• ANKRD26-related thrombocytopenia and myeloid malignancies..  122. 2013
• Detection of an NRAS mutation in Erdheim-Chester disease..  122. 2013
• MGUS prevalence in a cohort of AML patients..  122. 2013
• How low can you go?.  121. 2013
• Complement factor H mutations are present in ADAMTS13-deficient, ticlopidine-associated thrombotic microangiopathies..  121. 2013
• It takes 2 to thrombopoies in the vascular niche..  120. 2012
• Treating myeloma: the future is already here!.  120. 2012
• Nuclear JAK2..  118. 2011
• The treatment of essential thromobocytosis revisited..  118. 2011
• MCD & HHV-8 viral load..  118. 2011
• Tolvaptan inhibition of desmopressin effects on coagulation factors in a patient with decreased von Willebrand factor and polycystic kidney disease..  118. 2011
• ATG and RIC: not such a good match?.  117. 2011
• TMLI: a better TBI or more of the same?.  117. 2011
• Tregs served sunny-side up..  116. 2010
• RORing T cells target CLL and MCL..  116. 2010
• 3D trumps 2D when studying endothelial cells..  115. 2010
• The anergic B cell..  115. 2010
• Lack of evidence for direct involvement of Merkel cell polyomavirus (MCV) in chronic lymphocytic leukemia (CLL)..  115. 2010
• Cholesterol activates vascular niche and hematopoiesis..  115. 2010
• Response: Sample size and statistical comparisons of GVHD rates in pediatric Niemann-Pick disease patients..  115. 2010
• The proposed diagnostic criteria change for chronic lymphocytic leukemia: unintended consequences?.  113. 2009
• JAK2V617F: you can't have too much..  111. 2008
• A closer look at intravascular hemolysis (IVH) following intravenous anti-D for immune thrombocytopenic purpura (ITP)..  109. 2007
• Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7..  107. 2006
• Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells?.  106. 2005
• Imatinib mesylate in polycythemia vera..  103. 2004
• Epstein-Barr virus infection in Western European pediatric non-Hodgkin lymphomas..  102. 2003
• Role of surface IgM and IgD on survival of the cells from B-cell chronic lymphocytic leukemia..  99. 2002
• Beta-spectrin Promiss-ao: a translation initiation codon mutation of the beta-spectrin gene (ATG --> GTG) associated with hereditary spherocytosis and spectrin deficiency in a Brazilian family..  91. 1998
• Acute idiopathic thrombocytopenic purpura--management in childhood..  89. 1997
• Variation of fetal hemoglobin and F-cell number with the LCR-HS2 polymorphism in nonanemic individuals..  87. 1996
• Lymphoma classification proposal: clarification..  85. 1995
• CD2 expression and PML/RAR-alpha transcripts in acute promyelocytic leukemia..  81. 1993
• 2-Chlorodeoxyadenosine for multiple myeloma..  81. 1993
• Transcriptional analysis of the active X-chromosome in normal and clonal hematopoiesis..  81. 1993
• Changing causes of death in Pennsylvania's hemophiliacs 1976 to 1991: impact of liver disease and acquired immunodeficiency syndrome..  79. 1992
• Variant t(8;14) translocations in non-Burkitt's non-Hodgkin's lymphomas..  79. 1992
• Anti-D for the treatment of splenectomized patients with immune thrombocytopenic purpura..  78. 1991
• Anti-D Ig for treatment of immune thrombocytopenic purpura..  78. 1991
• Recombinant interferon alpha in the treatment of polycythemia vera..  77. 1991
• Minimal interferon-alpha doses for hairy cell leukemia..  75. 1990
• Variable breakpoints on Ph1-chromosome..  64. 1984
• Antithoracic duct lymphocyte globulin..  62. 1983
• Variant ph1 translocation in chronic myeloid leukemia..  54. 1979
• Pseudohyperkalemia and leukocytosis..  50. 1977
• ALPS or not? 2020
• Functional profiling to improve therapy in TCL. 2019
• BCL6 inhibition: a chronic GVHD twofer. 2019
• Lymphoma "benchmark" or "bench-smudge"? 2017
• HSP90, a chaperone that can make you SYK. 2017
• FBXO11: a novel germinal center B-cell regulator? 2016
• Cord blood T cells are "completely different". 2015
• cGVHD of skin: simple tools, great advances. 2012
• CARs and cancers: questions and answers. 2012
• Home free? Not after 3! 2011
• A new fish for the β2GPI hook: LPS! 2011
• A snappy new concept for APS. 2010
• Primary central nervous system lymphoma: coming or going? 2009
• COVID-19 in patients with CLL: improved survival outcomes and update on management strategies. 2021
• A novel TERC CR4/CR5 domain mutation causes telomere disease via decreased TERT binding. 2016
• A roadmap for discovery and translation in lymphoma. 2015
• Identifying familial myelodysplastic/acute leukemia predisposition syndromes through hematopoietic stem cell transplantation donors with thrombocytopenia. 2012
• Nonmyeloablative conditioning for relapsed follicular lymphoma. 2008
• Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection. 2004
• Reduced duration of cytopenias following melphalan conditioning and autografting for multiple myeloma. 2002
• Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. 2011
• Old is gold: frontline etoposide for pHLH..  143. 2024
• A new SAGA for AML: targeting SGF29 in AML..  143. 2024
• Targeting the cBAF complex in T-ALL..  143. 2024
• Pembrolizumab in PMBCL: can it go the distance?.  142. 2023
• TCL1A expression promotes aggressive biology in CLL..  141. 2023
• Acquired BAX mutations in AML..  141. 2023
• Claiming the mantle of the brain..  140. 2022
• Targeting IMiD-resistant T-cell lymphoma..  139. 2022
• POD24 in follicular lymphoma: time to be "wise"..  139. 2022
• Angiocrine ANGPTL2 executes HSC functions in endothelial niche..  139. 2022
• A BAX door to venetoclax resistance..  139. 2022
• Treatment of primary central nervous system lymphoma: still more questions than answers..  86. 1995
• The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms. 2021
• Optimizing treatment of HIV-associated lymphoma. 2019
• Transplant strategies in relapsed/refractory Hodgkin lymphoma. 2018
• Posttransplant chimeric antigen receptor therapy. 2018
• Diagnosis and classification of hematologic malignancies on the basis of genetics. 2017
• Antenatal management in fetal and neonatal alloimmune thrombocytopenia: a systematic review. 2017
• Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. 2017
• Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. 2016
• Role of the intestinal mucosa in acute gastrointestinal GVHD. 2016
• CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. 2016
• The 2016 revision of the World Health Organization classification of lymphoid neoplasms. 2016
• Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. 2016
• Emerging therapeutic drugs for AML. 2015
• How I treat catastrophic thrombotic syndromes. 2015
• The future of autologous stem cell transplantation in myeloma. 2014
• European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. 2013
• Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. 2013
• How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. 2012
• Second malignancies after multiple myeloma: from 1960s to 2010s. 2012
• IMWG consensus on maintenance therapy in multiple myeloma. 2012
• Hematopoietic stem cell engineering at a crossroads. 2011
• Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. 2011
• Transfusion-related acute lung injury: from bedside to bench and back. 2010
• The ITP syndrome: pathogenic and clinical diversity. 2009
• Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. 2008
• Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. 2006
• How I treat idiopathic thrombocytopenic purpura (ITP). 2005
• An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. 1999
• Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. 1999
• Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. 1998
• Platelets and shear stress. 1996
• Leukemia relapse after allogeneic bone marrow transplantation: a review. 1994
• A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. 1994
• Cancer genes and hematopoiesis. 1994
• Lowest dose interleukin-2 immunotherapy. 1993
• Biochemical mechanisms of platelet activation. 1989
• Bleeding and thrombosis in the myeloproliferative disorders. 1984
• Combination chemotherapy of advanced chronic lymphocytic leukemia: the M-2 protocol (vincristine, BCNU, cyclophosphamide, melphalan, and prednisone). 1982
• Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities. 2023
• Understanding CLL biology through mouse models of human genetics. 2021
• Splicing factor mutations in hematologic malignancies. 2021
• Leukemia secondary to myeloproliferative neoplasms. 2020
• Lenalidomide in follicular lymphoma. 2020
• How I treat primary mediastinal B-cell lymphoma. 2018
• Novel insights into the pathogenesis of T-cell lymphomas. 2018
• The potential for chemotherapy-free strategies in mantle cell lymphoma. 2017
• The relative utilities of genome-wide, gene panel, and individual gene sequencing in clinical practice. 2017
• EGFL7: a unique angiogenic signaling factor in vascular development and disease. 2011
• How I treat thalassemia. 2011
• How I treat the acquired von Willebrand syndrome. 2011
• How I treat: the selection and acquisition of unrelated cord blood grafts. 2010
• Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood? 2003

Identity

ISO Abbreviation

• Blood

Linking ISSN

• 0006-4971

International Standard Serial Number (ISSN)

• 0006-4971

Electronic International Standard Serial Number (EISSN)

• 1528-0020